1,3-dimethylbutylamine is an organic compound, specifically an amine, with the chemical formula **CH3CH(CH3)CH2CH(CH3)NH2**. It's a colorless liquid with a strong, ammonia-like odor.
**Importance in Research:**
1,3-dimethylbutylamine is not a widely studied or commonly used compound in research. It's not known for any particular biological activity or unique properties. This lack of established research interest likely stems from the following reasons:
* **Limited Availability:** The compound is not readily available commercially, and its synthesis might require specific chemical expertise.
* **Lack of Recognized Applications:** As a relatively simple amine, it doesn't possess any obvious features that would suggest it's particularly useful for medicinal chemistry or materials science.
* **Potential Toxicity:** As with most amines, it's likely to be corrosive and have a certain level of toxicity, which would need to be carefully considered for any research use.
**However, there are a few potential areas where 1,3-dimethylbutylamine *could* be interesting for research:**
* **Organic Synthesis:** It could serve as a starting material or building block for the synthesis of more complex organic compounds.
* **Materials Science:** Its amine group might be useful for creating polymers or other materials with specific properties.
* **As a Catalyst or Reagent:** It could be used as a catalyst or reagent in specific chemical reactions.
**Ultimately, without specific research goals or context, it's difficult to say why 1,3-dimethylbutylamine would be particularly important for research.** If you have a particular application in mind, it would be helpful to provide more details so that I can provide more focused information.
1,3-dimethylbutylamine: a stimulant; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 7908 |
| CHEMBL ID | 1447446 |
| SCHEMBL ID | 11229 |
| MeSH ID | M000610400 |
| Synonym |
|---|
| nsc-48080 |
| 2-pentanamine, 4-methyl- |
| 1,3-dimethylbutanamine |
| 2-amino-4-methylpentane |
| wln: zy1&1y1&1 |
| 1,3-dimethyl butylamine |
| 4-methyl-2-aminopentane |
| nsc48080 |
| butylamine,3-dimethyl- |
| 1,3-dimethylbutylamine |
| butylamine, 1,3-dimethyl- |
| 108-09-8 |
| NCGC00091725-01 |
| nsc 48080 |
| ai3-35094 |
| einecs 203-549-6 |
| ccris 4800 |
| un2379 |
| 1,3-dimethylbutylamine, 98% |
| 4-methylpentan-2-amine |
| 1,3-dimethylbutylamine [un2379] [flammable liquid] |
| D0694 |
| MLS002454356 , |
| smr001371983 |
| AKOS000134311 |
| NCGC00091725-02 |
| unii-kxp599h5r6 |
| 4-amino-2-pentanamine |
| 1,3-dmba |
| kxp599h5r6 , |
| pentergy |
| 4-amino-2-methylpentane |
| cas-108-09-8 |
| dtxcid205113 |
| dtxsid4025113 , |
| tox21_201157 |
| NCGC00258709-01 |
| STL168050 |
| AKOS017258605 |
| SCHEMBL11229 |
| bdbm74420 |
| 4-methyl-2-pentanamine |
| cid_7908 |
| 1,3-dimethylbutylamin |
| (1,3-dimethylbutyl)amine |
| 1,3-dimethyl-butylamine |
| GEO-03466 |
| CHEMBL1447446 |
| un 2379 |
| 1,3-dimethyl-n-butylamine |
| (+/-)-4-methyl-2-pentanamine |
| 2-pentanamine, 4-methyl |
| 1,3-dimethylbutylamine [who-dd] |
| (+/-)-1,3-dimethylbutylamine |
| dl-1,3-dimethylbutylamine |
| J35.117B , |
| J-002057 |
| mfcd00008088 |
| Q19595727 |
| N12044 |
| EN300-41148 |
| PD043017 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 31.6228 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 66.8242 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| geminin | Homo sapiens (human) | Potency | 0.1032 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 21.1317 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleoplasm | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nuclear body | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| chromatin | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||